- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03584516
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Linz, Austria, 04020
- Ordensklinikum Linz GmbH Elisabethinen
-
-
-
-
-
Antwerpen, Belgium, 02060
- ZNA Stuivenberg
-
Brussels, Belgium, 01000
- Institut Jules Bordet
-
Edegem, Belgium, 02650
- Universitair Ziekenhuis Antwerpen (Uza)
-
Gent, Belgium, 09000
- Universitair Ziekenhuis Gent
-
Leuven, Belgium, 03000
- Universitaire Ziekenhuis Leuven - Gasthuisberg
-
Liege, Belgium, 04000
- CENTRE HOSPITALIER UNIVERSITAIRE DE LI�GE - SART TILMAN
-
Roeselare, Belgium, 08800
- AZ Delta
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2P4
- University of Alberta
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Hospital Maisonneuve Rosemont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatchewan Cancer
-
-
-
-
-
Copenhagen, Denmark, 02100
- The Finsen Centre National Hospital
-
-
-
-
-
Turku, Finland, 20521
- Turku University Hospital
-
-
-
-
-
Amiens, France, 80054
- CHU Amiens Picardie - Hopital Sud
-
Angers, France, 49000
- Centre Hospitalier D'Angers
-
Grenoble Cedex, France, 38700
- CHU de Grenoble - Hôpital Albert Michallon
-
Marseille, France, 13273
- Institut Paoli-Calmettes
-
Nantes, France, 44000
- Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
-
Nice, France, 06800
- Chu de Nice - Hospital L Archet
-
Rennes, France, 35033
- Chu de Rennes - Hospital Pontchaillou
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Tours, France, 37000
- Chru Hopitaux de Tours Hospital Bretonneau
-
Vandoeuvre Les Nancy, France, 54511
- Hôpitaux de Brabois
-
-
-
-
-
Berlin, Germany, 12200
- Charite Berlin
-
Bonn, Germany, 00011
- Universitatsklinikum Bonn Aoer
-
Dresden, Germany, 01307
- University Clinic Carl Gustav Carus Technical University Dresden
-
Erlangen, Germany, 91054
- Universitaetsklinikum Erlangen - Medizinische Klinik 5
-
Essen, Germany, 45147
- Universitätsklinikum Essen
-
Halle, Germany, D06120
- UNIVERSIT�TSKLINIKUM HALLE (SAALE)
-
Hamburg, Germany, 20246
- University Medical Centre Hamburg-Eppendorf Centre of Oncology
-
Jena, Germany, 07740
- Universitaetsklinikum Jena
-
Koeln, Germany, 50937
- Universitätsklinikum Köln
-
Leipzig, Germany, 00341
- Selbststandige Abteilung Fur Hamatologie Und Internistische Onkologie
-
Mainz, Germany, 55131
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
Mannheim, Germany, 68167
- University Hospital Mannheim
-
Muenster, Germany, 48149
- Universitätsklinikum Münster
-
Munich, Germany, 81675
- Iii Medizinische Klinik Und Poliklinik Klinikum Rechts Der Isar Technische Universitat Munchen
-
Rostock, Germany, 18057
- Universitaetsmedizin Rostock
-
Tubingen, Germany, 72076
- Universitaetsklinikum in Tubingen
-
-
-
-
-
Chaidari, Greece, 124 62
- University Hospital of West Attica - Attikon
-
Thessaloniki, Greece, 57010
- General Hospital of Thessaloniki G. Papanikolaou
-
-
-
-
-
Haifa, Israel, 3109601
- Rambam Medical Center
-
Jerusalem, Israel, 91120
- Hadassah Hebrew University Medical Center Ein Karem Hadassah
-
Petach Tiqwa, Israel, 49100
- Rabin Medical Center - Beilinson Hospital
-
Tel Aviv-yafo, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Ancona, Italy, 60126
- CLINICA DI EMATOLOGIA, UNIVERSIT� POLITECNICA DELLE MARCHE
-
Bergamo, Italy, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Bologna, Italy, 40138
- L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA � MALPIGHI
-
Brescia, Italy, 25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
-
Catania, Italy, 95123
- Azienda Policlinico Vittorio Emanuele
-
Milan, Italy, 20122
- Fondazione Irccs Ca Granda Ospedale Maggiore
-
Milano, Italy, 20132
- Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
-
Modena, Italy, 41124
- A.O.U. di Modena - Policlinico
-
Napoli, Italy, 80131
- A.O.U. Federico II
-
Palermo, Italy, 90100
- Azienda Ospedaliera Ospedali Riuniti "Villa Sofia - Cervello"
-
Pavia, Italy, 27100
- Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
-
Reggio Calabria, Italy, 89133
- Azienda Ospedaliera Bianchi-Melacrino-Morelli Ospedali Riuniti
-
Roma, Italy, 00161
- Universita Degli Studi Di Roma La Sapienza - Umberto I Policlinico Di Roma - Centro Di Ematologia
-
Roma, Italy, 00168
- Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
-
Rozzano, Italy, 20089
- Irrcs Instituto Clinico Humanitas
-
San Giovanni Rotondo, Italy, 71013
- I.R.C.C.S. Casa Sollievo Della Sofferenza
-
Torino, Italy, 10126
- Azienda Ospedaliero Universitaria Citta Della Salute E Della Scienza
-
Udine, Italy, 33100
- Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
-
Verona, Italy, 37134
- Centro Ricerche Cliniche Di Verona (Crc)
-
-
-
-
-
Gdansk, Poland, 80-592
- Uniwersyteckie Centrum Kliniczne
-
Gliwice, Poland, 44-101
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy Oddzial W Gliwi
-
Poznan, Poland, 60-569
- Szpital Kliniczny Przemienienia Pańskiego
-
Warszawa, Poland, 02-106
- Mtz Clinical Research Sp. Zo.O.
-
-
-
-
-
Badalona, Spain, 08916
- Institut Catala D Oncologia
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
Granada, Spain, 18014
- Hospital Universitario Virgen de Las Nieves
-
L'hospitalet de Llobregat, Spain, 08908
- Ico Institut Catala D Oncologia
-
Madrid, Spain, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28007
- Hospital General Universitario Gregorio Maranon
-
Malaga, Spain, 29010
- Hospital Regional Universitario de Málaga
-
Palma, Spain, 07120
- Son Espases University Hospital
-
Pamplona, Spain, 31008
- Clinica Universidad de Navarra (Cun)
-
Salamanca, Spain, 37007
- Hospital Clinico Universitario de Salamanca
-
Santander, Spain, 39008
- Hospital Universitario Marques de Valdecilla
-
Santiago de Compostela, Spain, 15706
- Hospital Clínico de Santiago de Compostela
-
Valencia, Spain, 46010
- Hospital Clinico Universitario de Valencia
-
Valencia, Spain, 46009
- Hospital Universitario Y Politcnico de La Fe
-
-
-
-
-
Huddinge, Sweden, 141 86
- Karolinska University Hospital Huddinge
-
Lund, Sweden, 22185
- Skane University Hospital Lund
-
-
-
-
-
Zurich, Switzerland, 08091
- Universitätsspital Zürich
-
-
-
-
-
Bristol, United Kingdom, BS2 8ED
- Bristol Haematology & Oncology Centre
-
Cardiff, United Kingdom, CF14 4XW
- University Hospital of Wales
-
London, United Kingdom, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
London, United Kingdom, EC1A 7BE
- Barts Health Nhs Trust - St Bartholomews Hospital
-
London, United Kingdom, SE5 9RS
- King'S College Hospital (Nhs Foundation)
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Sutton, United Kingdom, SM2 5PT
- The Royal Marsden Nhs Foundation Trust - Sutton
-
Tooting, United Kingdom, SW17 0QT
- St. George's University Hospitals NHS Foundation Trust
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona Cancer Center - Out Pt.
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas For Medical Sciences - Winthrop P Rockefeller Cancer Institute
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
La Jolla, California, United States, 92093
- University of California San Diego Medical Center, Moores Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136-1002
- University of Miami Sylvester Comprehensive Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
Augusta, Georgia, United States, 30912
- Augusta University - Medical College of Georgia
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60714
- Illinois Cancer Specialists
-
Maywood, Illinois, United States, 60153-3328
- Loyola University Medical Center
-
Park Ridge, Illinois, United States, 60028
- Advocate Lutheran General Hospital - Oncology Specislists Sc
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5201
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Kansas
-
Westwood, Kansas, United States, 66160
- University of Kansas Hospital Authority
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112-2618
- Tulane University
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland - Greenebaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02111-1552
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota, Masonic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601-8550
- Hackensack University Medical Center
-
-
New York
-
Rochester, New York, United States, 14642-0001
- University of Rochester, James P. Wilmot Cancer Center
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
- Oncology Hematology Care, Inc
-
Cleveland, Ohio, United States, 44106-1716
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Abramson Cancer Center
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson University Hospitals
-
Pittsburgh, Pennsylvania, United States, 15224
- Western Pennsylvania Hospital
-
Pittsburgh, Pennsylvania, United States, 15232-1309
- University of Pittsburgh
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105-2108
- Avera Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
Nashville, Tennessee, United States, 37203
- Tri Star Bone Marrow Transplant
-
-
Texas
-
Austin, Texas, United States, 78704
- St David'S South Austin Medical Center
-
Dallas, Texas, United States, 75230
- Texas Oncology - Medical City Dallas
-
Dallas, Texas, United States, 75246
- Texas Oncology - Baylor Sammons Cancer Center
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Active, clinically diagnosed, moderate or severe cGVHD per NIH Consensus Criteria
- Underwent allogeneic stem cell transplantation (allo-HCT)
- Karnofsky Performance Status score ≥ 60%.
- Evidence of myeloid and platelet engraftment.
- Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.
Exclusion Criteria:
- Has received more than 3 days/72 hours of systemic corticosteroid treatment for cGVHD.
- Has received any other systemic treatment for cGVHD, including extracorporeal photopheresis (ECP).
- Prior treatment with a Janus kinase (JAK) inhibitor for acute GVHD, unless the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks before randomization.
- cGVHD occurring after a nonscheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence.
- Evidence of relapsed primary malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1 : Dose determination of itacitinib
itacitinib administered in combination with corticosteroids.
|
In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment.
In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment.
In Part 2, participants will receive the recommended dose from Part 1 expansion.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
|
Experimental: Part 1 : Dose expansion of itacitinib
itacitinib administered in combination with corticosteroids or corticosteroids alone.
|
In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment.
In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment.
In Part 2, participants will receive the recommended dose from Part 1 expansion.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
In Part 2, participants will receive matching placebo.
|
Placebo Comparator: Part 2 : itacitinib recommended dose from part 1
itacitinib or placebo administered in combination with corticosteroids
|
In Part 1dose determination participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment.
In Part 1 expansion, participants will receive either itacitinib administered orally either once daily or twice a day or corticosteroid alone based on the assigned treatment regimen according to cohort enrollment.
In Part 2, participants will receive the recommended dose from Part 1 expansion.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 : Dose Determination: Number of dose-limiting toxicities
Time Frame: 28 days
|
To identify an appropriate dose of itacitinib in combination with corticosteroids as initial treatment for moderate or severe cGVHD.
|
28 days
|
Part 2 : Response rate
Time Frame: Month 6
|
Defined as the proportion of participants demonstrating a complete response (CR) or partial response (PR) per National Institutes of Health (NIH) consensus guideline.
|
Month 6
|
Part 1 : Dose Expansion: Number of dose-limiting toxicities
Time Frame: 28 days
|
To identify an appropriate dose of itacitinib in combination with corticosteroids as initial treatment for moderate or severe cGVHD.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1, 1 expansion, and Part 2: Cmax of itacitinib when administered in combination with corticosteroids
Time Frame: Up to 28 days
|
Maximum observed concentration.
|
Up to 28 days
|
Part 1, 1 expansion, and Part 2: Cmin of itacitinib when administered in combination with corticosteroids
Time Frame: Up to 28 days
|
Minimum observed plasma or serum concentration over the dose interval.
|
Up to 28 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1, 1 expansion, and Part 2: Response rate
Time Frame: Up to 12 months
|
Defined as the proportion of participants who demonstrate a CR or PR per NIH consensus guideline.
|
Up to 12 months
|
Part 1: Time to response
Time Frame: Up to 36 months
|
Defined as the interval between randomization and first response.
|
Up to 36 months
|
Part 1, 1 expansion, and Part 2: Duration of response
Time Frame: Up to 36 months
|
Defined as the interval between first response and cGVHD progression, death, malignancy relapse, or initiation of new systemic cGVHD therapy.
|
Up to 36 months
|
Part 1, 1 expansion, and Part 2: Overall survival
Time Frame: Up to 36 months
|
Defined as the interval between the date of randomization and the date of death due to any cause.
|
Up to 36 months
|
Part 1, 1 expansion, and Part 2: Nonrelapse mortality
Time Frame: Up to 36 months
|
Defined as the proportion of participants who died due to causes other than malignancy relapse.
|
Up to 36 months
|
Part 2: Number of treatment-emergent adverse events
Time Frame: Up to 36 months
|
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment).
|
Up to 36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Rodica Morariu-Zamfir, MD, Incyte Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Bronchitis
- Bronchiolitis Obliterans
- Bronchiolitis
- Organizing Pneumonia
- Graft vs Host Disease
- Bronchiolitis Obliterans Syndrome
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Prednisone
Other Study ID Numbers
- INCB 39110-309
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Graft-versus-host Disease
-
University of LiegeTerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host DiseaseBelgium
-
Grupo Espanol de trasplantes hematopoyeticos y...CompletedChronic Graft-Versus-Host DiseaseSpain
-
Hospital Universitario Dr. Jose E. GonzalezRecruitingChronic Graft-versus-host-diseaseMexico
-
Shanghai General Hospital, Shanghai Jiao Tong University...Terminated
-
Universitätsklinikum Hamburg-EppendorfNovartis; Crolll GmbhCompletedChronic Graft-versus-host DiseaseGermany
-
Gruppo Italiano Trapianto di Midollo OsseoCompletedChronic Graft-Versus-Host DiseaseItaly
-
MedsenicCompletedImmune System Diseases | Chronic Graft-Versus-Host Disease
-
SCRI Development Innovations, LLCNovartisWithdrawnChronic Graft-Versus-Host DiseaseUnited States
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-sen University; Xinqiao Hospital...Recruiting
-
Navy General Hospital, BeijingRecruitingChronic Graft-versus-host DiseaseChina
Clinical Trials on Itacitinib
-
Incyte CorporationCompletedRheumatoid ArthritisUnited States, Puerto Rico
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSystemic SclerosisFrance
-
Incyte CorporationTerminatedBronchiolitis Obliterans SyndromeUnited States, Belgium, Canada
-
Incyte CorporationCompletedPolycythemia Vera | Myelofibrosis | ThrombocythemiaSpain, United States, Germany, Austria, Belgium, Italy, Poland
-
Imperial College LondonIncyte Biosciences UK LtdActive, not recruitingAdvanced Hepatocellular CarcinomaUnited Kingdom
-
Incyte CorporationAvailableSTAT1 Gain-of-Function Disease
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)Canada, United States, Australia
-
Incyte CorporationActive, not recruitingChronic Graft Versus Host Disease | Myelofibrosis | Postlung Transplant (Bronchiolitis Obliterans)United States, Spain, Italy, Germany, Belgium, Austria, Israel, Canada, Greece